Opinion/decision on a Paediatric investigation plan (PIP): Evusheld, tixagevimab,cilgavimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Infectious diseases, PIP numb

Opinion/decision on a Paediatric investigation plan (PIP): Evusheld, tixagevimab,cilgavimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Infectious diseases, PIP number: P/0119/2023

Human medicines European public assessment report (EPAR): Lamivudine Teva, lamivudine, Date of authorisation: 23/10/2009, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Lamivudine Teva, lamivudine, Date of authorisation: 23/10/2009, Revision: 14, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness